<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Genestrat® Genomic Test

Swift and actionable, blood-based mutation results.

Identify your patient’s actionable lung cancer mutations.

Guideline-recommended, blood-based mutation results within 72 hours.

What is the GeneStrat® test?

  • Delivers guideline-recommended, blood-based mutation results: EGFR | ALK | ROS1 | RET | BRAF | KRAS
  • Results within 72 hours can expedite time to treatment initiation and complement tissue-based testing1,2
  • Drives treatment strategy and facilitates monitoring

Download GeneStrat report

Testing Platform

  • Measures circulating cell-free DNA and RNA using Droplet Digital™ PCR (ddPCR)
  • Highly sensitive and specific mutation detection
  • GeneStrat is clinically validated3,4

Learn more

The genes tested in the GeneStrat® test are covered by Medicare and many private payers.

Not restricted by stage of NSCLC or recurrence. Multiple tests per patient per cancer when medically necessary.

Learn more about Reimbursement

With tissue-based testing, 4% of patients had molecular test results prior to start of front-line treatment. However, with Biodesix Lung Reflex®, 72% of patients have molecular test results available.1

Expediting Time to Treatment with Swift and Actionable Results

expediting time graphic

Complementing Tissue Testing

complementing tissue testing graphic

Blood-based testing is 3 weeks faster than tissue-based testing.

Save tissue for diagnostic evaluation, PD-L1 testing and broad genomic profiling.2

Accurate, actionable genomic results

Our data

Case Studies

Learn how some of the industry’s leading experts are using Biodesix Lung Reflex® testing in their practice.


Jonathan Kurman, MD

Froedtert & the Medical College of Wisconsin


Michael Pritchett, DO, MPH

Chest Center of the Carolines at FirstHealth of the Carolinas

Interested in ordering a test kit?


Get in touch

Contact us

Data library

Discover more
  1. Bowling M, et al. J Clin Oncol 36, 2018 (suppl; abstr e18519)
  2. Boyle T, et al. Poster presentation: AMP annual meeting. Salt Lake City, UT; 2017.
  1. Mellert, et al. J Mol Diagn. 2017, 19: 404-416.
  2. Mellert, et al. J Vis Exp. 2018 Apr 5;(134).